The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

Phase 2

Completed

• Conditions: Atherosclerosis
• Interventions: Drug: MK0633

• Registration Number: NCT00421278
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease

Detailed Description

Not available

Study Timeline

• Study Start: 2006-11
• Primary Completion: 2006-12
• Study Completion: 2007-01
• Study First Submitted: 2007-01-09
• Study First Submitted QC: 2007-01-09
• Study First Posted: 2007-01-11
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-21
• Last Update Posted: 2016-01-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 180

Inclusion Criteria

• Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease
• Inflammatory marker found in your blood, known as hsCRP > 0.5 mg/L

Exclusion Criteria

• Age < 40 or > 85
• Female
• Heart attack, coronary artery bypass, stroke or unstable angina in last 3 months
• Liver diseased or abnormalities
• HIV infection
• Lupus, rheumatoid arthritis, cancer <5 years

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	MK0633	Arm 1: Drug

Primary Outcome Measures

Name	Time	Method
To evaluate the effects of the drug, MK 0633, on an inflammatory marker in your blood that may affect the plaque in the arteries, know as atherosclerosis	4 Weeks